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ITGB1-dependent upregulation of 
Caveolin-1 switches TGFβ signalling 
from tumour-suppressive to 
oncogenic in prostate cancer
Teijo Pellinen1,2, Sami Blom  1, Sara Sánchez2, Katja Välimäki1, John-Patrick Mpindi1, Hind 
Azegrouz3, Raffaele Strippoli2, Raquel Nieto3, Mariano Vitón3, Irene Palacios3, Riku Turkki  1, 
Yinhai Wang  1,8, Miguel Sánchez-Alvarez2, Stig Nordling4, Anna Bützow4, Tuomas Mirtti  1,4,5, 
Antti Rannikko6, María C. Montoya  3, Olli Kallioniemi  1,7 & Miguel A. del Pozo2
Caveolin-1 (CAV1) is over-expressed in prostate cancer (PCa) and is associated with adverse prognosis, 
but the molecular mechanisms linking CAV1 expression to disease progression are poorly understood. 
Extensive gene expression correlation analysis, quantitative multiplex imaging of clinical samples, and 
analysis of the CAV1-dependent transcriptome, supported that CAV1 re-programmes TGFβ signalling 
from tumour suppressive to oncogenic (i.e. induction of SLUG, PAI-1 and suppression of CDH1, DSP, 
CDKN1A). Supporting such a role, CAV1 knockdown led to growth arrest and inhibition of cell invasion 
in prostate cancer cell lines. Rationalized RNAi screening and high-content microscopy in search for 
CAV1 upstream regulators revealed integrin beta1 (ITGB1) and integrin associated proteins as CAV1 
regulators. Our work suggests TGFβ signalling and beta1 integrins as potential therapeutic targets in 
PCa over-expressing CAV1, and contributes to better understand the paradoxical dual role of TGFβ in 
tumour biology.
Epithelial-to-mesenchymal transition (EMT) is associated with the disruption of the normal structure of the 
epithelium and the invasion of carcinoma cells into the surrounding stroma1. EMT-associated epithelial plas-
ticity is a relevant phenomenon in prostate cancer (PCa) progression2. A hallmark of EMT is the decreased or 
aberrant expression of the adherens junction protein E-cadherin3. In PCa, decreased E-cadherin expression 
has been shown to correlate with clinical disease progression in multiple independent studies4–8. A pivotal reg-
ulator of EMT is transforming growth factor beta (TGFβ)9. Shutdown of canonical TGFβ signalling through 
down-regulation or deletion of the transcriptional effector protein, SMAD4, promotes cell growth and prolif-
eration in epithelium, and can therefore lead to carcinogenesis10. However, in advanced stages of cancer, the 
growth-suppressive function of TGFβ is often subverted to promote invasion and EMT, independent of SMAD 
proteins11. Indeed, there is evidence that TGFβ expression correlates with PCa progression and poor clinical 
outcome12,13. Also, TGFβ signalling promotes invasive growth and metastasis of PCa14–17. However, and despite 
its outstanding relevance, the principles determining this “Janus” behaviour of the TGFβ pathway have not been 
fully elucidated.
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Caveolin-1 (CAV1) is a cholesterol-binding scaffold protein which functions in membrane dynamics, uptake 
of certain viruses, lipid metabolism, signalling, mechano-sensing and membrane mechano-protection18. CAV1 
is known to homo-oligomerize, hetero-oligomerize with CAV2, and assemble with cavins (1–4) to form mem-
brane invaginations called caveolae. CAV3 is the muscle-specific caveolin, and the three isoforms are typically 
expressed in tissues subjected to wide variations in mechanical stress (endothelium, muscle, lung, fat, etc.). CAV1 
positively regulates integrin signalling to promote cell growth through the RAS-ERK pathway19. Conversely, 
integrin-mediated cell adhesion may dramatically affect the localization of CAV120. However, how CAV1 expres-
sion is regulated is poorly understood. Moreover, CAV1 interacts with numerous other signalling proteins and 
pathways, but its impact is highly contextual and tissue-specific. This conditional functionality is also reflected in 
its suggested roles in cancer, both as a potential suppressor in early disease stages and a proto-oncogene in later 
stages21. The tumour-promoting role of CAV1 is associated both with resistance to apoptosis22,23 and increased 
cancer cell migration or invasion24. CAV1 knock-down inhibits migration of PCa cell lines in vitro25 and reduces 
lymph node and lung metastasis in experimental metastasis assays26, suggesting an active role for CAV1 in PCa 
progression. In addition, CAV1 may either promote or inhibit EMT depending on tissue context27–30. Previous 
work in PCa suggests that CAV1 induces cell invasion and inhibits E-cadherin expression, which are important 
hallmarks of EMT31. Furthermore, CAV1 overexpression is associated with aggressive disease and poor clinical 
outcome32,33. However, the molecular pathways promoting CAV1 overexpression – linked to increased invasion 
and potential resistance to apoptosis – are still largely unknown in PCa.
Here, we show that CAV1 expression associates with oncogenic EMT markers and inversely correlates with 
E-cadherin expression in clinical PCa tissue samples. In addition, we found that CAV1 promotes the expression 
of oncogenic TGFβ targets, but reduces the expression of TGFβ-induced p21 growth inhibitory protein in PCa 
cells. Rationally-targeted functional image-based RNAi screenings revealed that CAV1 expression is controlled 
by beta1 integrins and integrin-related signalling. Multiplexed immunohistochemistry (IHC) and image analysis 
revealed a high degree of co-expression between beta1 integrin (ITGA2/B1) and CAV1 both in cell lines in vitro 
and in clinical PCa tissue. Our findings suggest that increased CAV1 levels are not merely a consequence, but an 
active driving element of PCa towards a more mesenchymal phenotype.
Results
CAV1 expression associates with a mesenchymal gene signature. CAV1 expression has been 
shown to be up-regulated in PCa and to associate with poor prognosis32–34. Nevertheless, despite these reported 
links, the underlying mechanisms by which CAV1 dysregulated expression determine an aggressive phenotype 
in PCa are currently not well understood. To gain further insight into the functional programs associated with 
CAV1 expression in PCa, we queried extensive transcriptome datasets to find signatures exhibiting correlation 
with CAV1 expression (see Methods). Gene subsets were classified into epithelial and mesenchymal signatures 
across different epithelial and mesenchymal cell lines using a principal component analysis (PCA) (Fig. 1a; see 
Supplementary Table S1 for cell lines). We found that the expression of CAV1 was much higher in mesenchy-
mal than in epithelial cells, and CAV1 was among the top 100 ‘mesenchymal-specific’ genes (see Supplementary 
Table S2 and S3 for top 100 mesenchymal and top 100 epithelial genes, respectively). In a panel of well-charac-
terized prostate and breast cancer cell lines, hierarchical clustering of the top 100 mesenchymal and the top 100 
epithelial genes revealed two mesenchymal sub-clusters ‘A’ and ‘B’ (Fig. 1b), defined as “pure” and “transition” 
clusters, respectively. The genes of the “pure” mesenchymal cluster were exclusively up-regulated in mesenchymal 
Figure 1. CAV1 associates with EMT gene expression signatures. (a) PCA analysis across extensive cancer cell 
line datasets classifies CAV1 as a robust component of mesenchymal gene expression signature. (b) Hierarchical 
clustering across selected epithelial and mesenchymal cell lines of the highest scoring differentially expressed 
genes defines a subset of genes described as “transitional EMT”, which includes CAV1 (cluster B).
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cells, such as SPARC and a few ECM structural proteins, whereas the genes in the “transition cluster” were not 
only highly expressed across mesenchymal cell lines but also substantially expressed in a number of epithelial cell 
lines. This “transition cluster”, which comprised six genes (e.g. SERPINE1 (PAI-1), SNAI2 (SLUG), MMP1, VIM 
(Vimentin), TGFBI, and CTGF)) tightly correlated with CAV1 expression across all cell lines surveyed. Thus, 
these orthogonal datasets potentially dissect gene subsets specific for EMT expression signature, and support that 
CAV1 could actively contribute to the regulatory programs driving EMT in PCa.
As the aberrant expression of E-cadherin is a hallmark of EMT and is associated with poor clinical outcome 
in PCa6, we set out to study the association of CAV1 and E-cadherin expression in human PCa tumours. Briefly, 
we applied fluorescence-based multiplex immunohistochemistry35, which allowed both visual scoring and dig-
ital quantitative image analysis. Importantly, the method allowed digital segmentation of the epithelium from 
stroma using pan-cytokeratin (panCK) as epithelial marker. We observed a strong association between CAV1 
expression and reduced E-cadherin expression in cancer epithelia (panCK+/KRT5−), but not in KRT5-positive 
regions, which consist mainly of non-malignant epithelium (benign, PIN), but may also contain malignant tissue 
(intraductal carcinoma of the prostate, IDCP) (Fig. 2a). This effect was evident not only in sections across dif-
ferent cancer patients (inter-tumour association), but also across different areas within the same patient sample 
(intra-tumour association) (Supplementary Fig. S1a–b). To further validate these observations, we visually ana-
lysed a set of PCa patient samples (TMA_2; n = 70) for CAV1 (visual scores 0–3) and E-cadherin (visual scores 
0–5). Patients with high CAV1 expression showed lower E-cadherin expression (corr r = −0.60; p = 4E-8; n = 70). 
In addition, we digitized the sections and performed automatic image analysis of CAV1 and E-cadherin expres-
sion in KRT5-positive glands (n = 239) and in cancerous areas (panCK+/KRT5−) (n = 263). Consistent with 
visual scoring, we found a significant inverse correlation of CAV1 and E-cadherin in cancerous areas (Pearson 
Figure 2. Patients with moderate-to-high CAV1 expression have a partial loss of E-cadherin. (a) Two different 
antibody cocktails were applied to get information on CAV1 and E-cadherin (ECADH) expression in PCa 
epithelium. Pan-cytokeratin (panCK) was used as a marker for epithelium, cytokeratin-5 (KRT5) for basal 
epithelium, and Hoechst for nuclei. Example images of patients 1, 2, and 3 showing strong, medium, and weak 
E-cadherin expression, respectively, with strong CAV1 expression only in the patient 3 (scale bar = 50 µm). 
(b,c) Digital analysis of CAV1 and ECADH expression in PCa patients (n = 70) within KRT5-positive or KRT5-
negative epithelial areas. r = pearson correlation. Arbitrary unit (a.u.) here is defined as the average protein 
expression intensity measured: total channel intensity (1–255) divided by total area in pixels.
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corr r = −0.35; p = 4E-8), whereas a weak positive correlation was found in KRT5-positive glands (Pearson corr 
r = + 0.14; p = 0.01) (Fig. 2b,c). Furthermore, we found that CAV1 expression was generally higher (p = 1.8e-13) 
and E-cadherin expression lower (p = 8.4e-12) in cancerous epithelium as compared to KRT5-positive epithe-
lium. Analysis of mRNA expression data from the GeneSapiens database36 recapitulated the inverse correlation 
of CAV1 and CDH1 (E-cadherin) specifically in clinical PCa samples (correlation coefficient = −0.19; p < 0.001; 
n = 460), but not in the benign prostatic tissue (correlation coefficient = 0.034; p = 0.63; n = 208) (Supplementary 
Fig. S1c). In accordance with our correlation analysis in cell lines (see Fig. 1), the inverse correlation between 
CAV1 and E-cadherin expression in primary PCa epithelium prompted a model whereby CAV1 actively partici-
pates in the rewiring of cell signalling towards EMT during PCa progression.
CAV1 polarizes the reprogramming of TGFβ-associated transcriptomic signatures. Because 
TGFβ is one of the most potent inducers of EMT and a well-established regulator of E-cadherin expression2, 
we decided to explore TGFβ-associated regulatory events upon CAV1 silencing in PCa cells. We performed 
a genome-scale microarray analysis of PC-3 cells stably expressing CAV1-targeting shRNA (L-shCAV1) or 
non-targeting shRNA (L-shCTR) as control. Intriguingly, CAV1 silencing differentially affected distinct subsets of 
bona fide TGFβ targets: 24 genes were down-regulated and 22 genes were up-regulated (Supplementary Table S4). 
Moreover, CAV1 silencing reduced the expression of TGFβ target genes in the mesenchymal gene cluster but 
increased those in the epithelial gene cluster (Supplementary Tables S4 and S5). Functional network analysis of 
the differentially regulated genes recapitulated the bimodal segregation of TGFβ targets in two modules – first 
predominantly comprised of genes down-regulated upon CAV1 silencing (“ECM remodelling-invasion”) and the 
second composed of genes showing inverse correlation with CAV1 (“Inflammation”) (Supplementary Fig. S2). 
Interestingly, both modules were enriched in distinct genes for potential upstream regulatory kinases, further 
suggesting a functional coherence of the genes within these modules (Supplementary Fig. S2). We confirmed 
the expression of a subset of these genes by Western blotting or qPCR, followed by a validation upon CAV1 
knockdown with an independent CAV1 siRNA duplex (Fig. 3a; Supplementary Fig. S3a,b). CAV1 silencing in 
three prostate cell lines reduced the expression of two well-characterized mesenchymal TGFβ targets, SLUG 
(SNAI2) and PAI-1 (SERPINE1) (Fig. 3a,b; Supplementary Fig. S3a,b, S3d,e), but increased the expression of 
TGFβ targets that are known positive regulators of epithelial integrity (DSP = desmoplakin; ITGB4 = integrin 
beta4; CDH1 = E-cadherin) (Fig. 3a; Supplementary Fig. S3b; Supplementary Table S4). Critically, the suppres-
sion of CAV1 expression did not alter SMAD3 phosphorylation, nor affected the subcellular localization of either 
SMAD2 or SMAD3 (Fig. 3a; Supplementary Fig. S3b,c), supporting that the observed effects are not likely a con-
sequence of primary disruption of, or insensitivity to TGFβ stimulation, but rather a result of selective rewiring 
of networks downstream from CAV1.
Because CAV1 silencing affected the phenotype of PC-3 cells cultured on Matrigel (Fig. 3c), we inquired 
whether CAV1 could also regulate the levels of the TGFβ-induced growth inhibitor, p21 (CDKN1A). First, we 
found that p21 expression was increased upon TGFβ stimulation in PC-3 cells in three culture conditions: on 
top of Matrigel (Fig. 3c), in suspension culture (Fig. 3d), and inside collagen type I (Fig. 3e). However, we also 
observed that CAV1 silencing alone increased p21 expression, mimicking the effect of TGFβ. Importantly, CAV1 
silencing synergized with TGFβ stimulation leading to even higher p21 expression.
CAV1 promotes mesenchymal phenotype in prostate cancer cells. As CAV1 knock-down influ-
enced EMT-associated signalling in PCa, we decided to explore the effects of CAV1-silencing on cell motility and 
invasion phenotypes in PCa cell lines. First, DU145 cells were cultured in the presence or absence of TGFβ on 
two different substrates (plastic vs. fibronectin (FN) coated plates). In agreement with the suggested proactive 
role of CAV1 in EMT, CAV1 silencing led to reduced scattering and to increased E-cadherin expression upon 
exposure to FN and/or TGFβ as compared to wild-type control (Fig. 4a,b). Further, CAV1 depletion inhibited 
invasion in a 3D cell culture model of highly invasive PC-3 cell line (Fig. 4c–e), and this effect was evident either 
in the presence or absence of TGFβ (Fig. 4f,g). In agreement with our previous analyses of primary tumours, 
immunocytochemistry of a 3D-cell culture model upon formalin-fixation and paraffin-embedding (FFPE) reca-
pitulated the inverse correlation in CAV1 and E-cadherin protein expression (Fig. 4f, right panel). In addition, 
CAV1 knock-down significantly suppressed 3D cell growth, which was further inhibited by the addition of TGFβ 
(Fig. 4h). These results highlight the role of CAV1 in promoting EMT and invasive growth of PCa cells.
Targeted image-based screens across CAV1 co-expressing transcriptome subsets reveal novel 
beta1 integrin-dependent modules driving CAV1 expression. Given that CAV1 promoted invasive 
phenotypes and was found to be over-expressed in a subset of PCa patients, characterization of the elements and 
architecture of the upstream signalling controlling CAV1 levels is warranted. To attain increased sensitivity for 
high-confidence genes and functional pathways participating in CAV1-associated phenotypes, we first performed an 
independent, CAV1-centered co-expression profiling across transcriptomic data on 300 different cell lines derived 
from 25 different tissue types37. Top 500 genes correlating with CAV1 expression were queried for annotated func-
tional categories (David Gene Functional Classification tool; http://david.abcc.ncifcrf.gov; ref.38). Top GoTerm cat-
egories included cell adhesion (p = 6.9E-16), cell-substrate junction (p = 4.1E-16), and cytoskeletal protein binding 
(p = 4.2E-14) (Supplementary Table S6), which reflect functional annotations for CAV1. We curated these highly 
co-expressed gene sets as well as functionally-related genes and performed a targeted image-based RNAi screen in 
three different prostatic cell lines to detect the effect of specific gene-silencing on CAV1 (Supplementary Table S7 
for gene list; Supplementary Table S8 for siRNAs). In addition to CAV1, we also quantified the expression of inte-
grin beta1 (ITGB1) (Supplementary Fig. S4a for z-prime values), because it is known to physically interact with 
CAV139 but also because ‘cell adhesion’ scored as the functional category correlating strongest with CAV1 expres-
sion. Examples of representative images and scatter plots for CAV1 and ITGB1 staining intensities across the tested 
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conditions are shown in Figure 5a and Supplementary Figure S4b, respectively. The screen results are summarized 
in Figure 5b. The screen revealed a highly significant correlation (r = 0.47–0.67; p < 0.01) between ITGB1 and CAV1 
expression in all three prostate cell lines studied (Fig. 5c). Mechanistically, all four ITGB1 siRNAs resulted in a 
pronounced down-regulation of CAV1 protein expression in PC-3 cells – but not vice versa, supporting a specific 
hierarchical dependency of CAV1 expression on ITGB1 levels (Fig. 5d). The result was further validated by Western 
blot analysis (Fig. 5e), and also by showing that cell adhesion to integrin beta1 substrates, fibronectin or Matrigel, 
induces CAV1 expression (Supplementary Fig. S4c). The finding that various ITGB1 binding alpha subunits (ITGA1, 
ITGA2, ITGA3, ITGA5, ITGA6) and extracellular matrix (ECM) proteins that bind integrins (fibronectin, laminins 
and collagens), as well as proteins linking integrins with the cytoskeleton (e.g. FERMT2/Kindlin-2, PXN/paxillin, 
ACTN1/alpha-actinin, ILK/integrin-linked kinase), were identified as positive CAV1 regulators (Fig. 5b), provides 
further evidence for the role of beta1 integrin as a CAV1 upstream regulator.
CAV1 over-expression is strongly associated with ITGB1 expression in PCa clinical samples. 
As we showed that ITGB1 is an upstream regulator of CAV1 expression and the two proteins are correlated in 
vitro, we asked if this correlation could be validated in a large clinical prostate cancer cohort. For this, CAV1 and 
ITGB1 were analysed in a cohort of 435 patients (TMA_1) in a tissue microarray (TMA) format, including one 
core from a benign area and three cores from cancer areas in each patient. CAV1 expression in cancer was strong 
in 11.5% (CAV1 average score x ≥ 2), moderate in 14% (score 1 < x < 2), weak in 48% (score 0 < x ≤ 1), and neg-
ative in 27% (score x = 0) of the patients (Table 1). Most of the patients (91%) showed either weak (42%) or neg-
ative (49%) CAV1 expression in the benign luminal epithelium. In accordance with previous studies, the mean 
expression of CAV1 was 71% higher in cancer compared to the benign tissue (p < 0.001, Welch’s one-way 
ANOVA). Importantly, also the mean expression of ITGB1 was higher in the cancer areas (215%; p < 0.001, 
Welch´s one-way ANOVA). Representative images of cancer areas with different expression scores for CAV1 
and ITGB1 as well as a control experiment for CAV1 antibody IHC validation are shown in Figure 6a and b, 
Figure 3. CAV1 promotes oncogenic TGFβ signalling. (a) PC-3 cells silenced and treated with TGFβ as 
indicated. pSMAD3 was used as a positive control for TGFβ induction. (DSP = Desmoplakin). (b) Same as 
(a), except cells were DU145 (left panel) or PNT2 (right panel). (c) PC-3 cells were grown on top of Matrigel 
(50%), silenced as indicated, and treated with TGFβ for 72 h. Phase contrast bright-field (left panel) and high 
magnification dark-field images (upper right panel), with indicated targets blotted from a replicate experiment 
(lower right panel). Scale bars 300 µm (left) and 30 µm (right). (d) PC-3 cells were cultured in suspension, 
silenced as indicated, and treated with TGFβ. (e) Same as (d), except cells were grown inside collagen type I.
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Figure 4. Caveolin-1 promotes EMT and invasiveness, but reduces TGFβ-induced growth inhibition. (a) 
Phase contrast images of RNAi-treated DU145 cells on plastic (pl) or fibronectin-coated cell culture plates 
(Fn) induced with TGFβ (1 ng/ml) for 70 hours (size bar = 50 µm). (b) Same as (a), but Western blot analysis 
after 72 hours. (c) Representative images of side projection views of invasion assays in 50% Matrigel towards 
serum gradient. PC-3 cells were silenced as indicated and stained with fluorescent phalloidin and Hoechst 
33342 and imaged in x-y-z dimensions using confocal microscope. L-shCtrl and L-shCAV1 state for Lentiviral 
constructs for control-silencing and CAV1-silencing, respectively. (d) A replicate invasion experiment of 
(c), but now cells were analysed using Western blotting. (e) Quantification of invasive growth from three 
independent experiments. The results show fold change of growth area measured. *p < 0.05; two-tailed t 
test. (f) Same as (c), but now cells cultured in collagen type I (1 mg/ml) with or without TGFβ. The images 
are maximum projections from consecutive z-planes as indicated. The silencing of CAV1 and subsequent 
up-regulation of ECADH was evaluated from parallel 3D experiments, which were processed for fixation 
and parafinization for immunocytochemistry (right panels) (scale bar = 50 µm). (g) Relative end-point cell 
counts in collagen invasion assays from (f) in different planes as indicated. Results are from three independent 
experiments (pl. = confocal planes). (h) 3D cell growth measured as total cell count in all the confocal planes. 
n = 3 independent experiments; *p < 0.05; **p < 0.01; ***p < 0.001; two-tailed t test. Error bars represent mean 
standard deviation.
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respectively. CAV1 and ITGB1 expression strongly correlated across all tissue cores (Spearman rho = 0.492; 
p < 0.001). Neither CAV1 nor ITGB1 expression associated with Gleason score or pathological tumour stage (pT) 
(Tables 2 and 3). To support these data, a multiplexed 4-color IHC and automatic image analysis demonstrated 
that epithelial CAV1 correlates not only with ITGB1 but also with ITGA2 and ITGA6 – alpha integrin subunits 
forming dimers with ITGB1 (Supplementary Fig. S5).
Discussion
In this study, we contribute novel insights onto how CAV1 promotes EMT and invasion in PCa. We show that 
CAV1 is up-regulated in tumour epithelium in a subset of PCa patients, and this up-regulation is strongly asso-
ciated with a significant loss of E-cadherin, a hallmark of mesenchymal conversion. In agreement with such a 
functional role for CAV1 in PCa, knockdown of CAV1 abolished EMT phenotypic traits and invasiveness in PCa 
cells. Molecular profiling and unbiased analysis of extensive datasets revealed that CAV1 selectively promotes a 
pro-oncogenic program from TGFβ signalling, while attenuating subsets of TGFβ targets established as tumour 
suppressors. Finally, we show that beta1 integrins positively regulate CAV1 expression in vitro – an observation 
Figure 5. ITGB1 is an upstream regulator of CAV1 expression. (a) Example images of the RNAi screen 
read-outs of PC-3 cells silenced as indicated (size bar = 10 µm). (b) Positive regulators of CAV1 expression 
indicated as number of siRNAs with average z-score higher than 1.0 in three cell lines (PC-3, PNT2, DU145). 
Each z-score is a mean of three replicate experiments. (c) Correlation of CAV1 and ITGB1 expression in three 
prostate cell lines. Data was extracted from the screen results using siCTRL wells from one single replicate 
plate. r = pearson correlation. (d) Silencing effects of indicated siRNAs on ITGB1 (upper panel) and CAV1 
(lower panel) expression at single-cell level in PC-3 cell line from one replicate experiment. Each dot represents 
expression of ITGB1 or CAV1 in a single cell. Median values are indicated as bars. *p < 0.05; two-tailed t test. 
Each ITGB1 siRNA effect was compared with the mean result of the two siCTRLs. (e) Same as in (d), but now 
an independent experiment with cellular lysates analysed using WB.
CAV1 score Benign, n (%) Cancer, n (%) p-value1
Negative (x = 0) 215 (49.4) 117 (26.9) <0.001
Weak (0 < x ≤ 1) 183 (42.1) 207 (47.6)
Moderate (1 < x < 2) 0 (0) 61 (14.0)
Strong (2 ≥ x) 3 (0.69) 50 (11.5)
Total 401 (100) 435 (100)
Table 1. CAV1 expression distribution in benign and cancer tissue areas in TMA_1. 1The difference of CAV1 
expression between benign and cancer areas was analysed using oneway ANOVA.
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that is consistent with a strong positive correlation between beta1 integrin and CAV1 expression in prostatectomy 
patient cohort using both conventional IHC and multiplexed quantitative fluorescence analysis.
A central observation in our study was that CAV1 specifically promotes the expression of oncogenic TGFβ 
targets including SLUG and PAI-1, apart from down-regulating E-cadherin and inhibiting the basal and 
TGFβ-induced expression of the cyclin-dependent kinase inhibitor, p21. Previously, SLUG was shown to promote 
Figure 6. CAV1 overexpression associates with ITGB1 expression in clinical PCa. (a) Example images of 
CAV1 antibody (BD clone 2297; 1/1000) and ITGB1 antibody (EP1041Y; 1/500) IHC of patient cancer cores 
in TMA_1 cohort with expression scores 0 and 3. (b) A control experiment showing high specificity of CAV1 
antibody (clone 2297). Silencing of CAV1 in PC-3 cell line substantially decreases the CAV1 expression in IHC 
staining of paraffin-embedded sample section processed similarly as the tissue sections in the TMA cohort for 
CAV1 staining (TMA_1) (scale bar = 50 µm).
Gleason score n (%) CAV1 negative CAV1 weak CAV1 moderate CAV1 strong χ2(p-value)
≤6 80 (24) 12 45 13 10
0.075
7 200 (59) 57 90 36 17
8≤ 57 (17) 21 23 6 7
Total1 337 (100) 90 158 55 34
Pathological stage n (%)
0.154
≤pT2 182 (58) 41 89 35 17
pT3≤ 129 (42) 40 57 16 16
Total2 311 (100) 81 146 51 33
Table 2. CAV1 expression association with pathological variables in TMA_1. 1Patients who received neo-
adjuvant therapy or were missing Gleason score were removed from the analysis. 2Patients who received neo-
adjuvant therapy or were missing stage information were removed from the analysis.
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TGFβ-mediated EMT and invasion in PCa cell lines40–44, whereas PAI-1 was essential for TGFβ and EGF mediated 
cell scattering in an EMT model of transformed human keratinocytes45. Supporting our findings, Liang and others27  
showed that CAV1 induces the expression of SLUG and inhibits that of E-cadherin in bladder cancer cell lines. 
While no previous reports elucidate the molecular pathways explaining the tumour suppressive-to-oncogenic 
switching of TGFβ signalling in PCa, other studies in different cancers point-out RAS-MEK-MAPK signalling as 
an important escape mechanism from the growth inhibitory effects of TGFβ46–48. Our findings demonstrate that 
CAV1 promotes invasive growth and inhibits the growth inhibitory effects of TGFβ, as well as reveal the specific 
suppressive and oncogenic transcriptional targets associated with TGFβ stimulation.
We have previously shown, as opposed to PCa cells, that CAV1 deficiency induces EMT in primary mesothelial cells 
during peritoneal dialysis (PD)49. This apparent contradiction may derive from cell-specificity and from the differences 
in the tissue microenvironment, as in PD the peritoneum is exposed to pro-inflammatory and pro-fibrotic stimuli. 
Strippoli and others49 showed that CAV1 inhibits the RAS-MEK-ERK activity in primary mesothelial cells thus con-
tributing to inhibition of EMT by this pathway. In the cancers of prostate, colon, lung, melanoma, and Ewing sarcoma, 
CAV1 has been shown to activate the RAS-ERK-MEK signalling and promote cancer progression50–54, demonstrating 
that in certain cancer tissue the role of CAV1 in this pathway is opposite as compared to mesothelial cells. Likewise, 
in breast cancer, where CAV1 role has been suggested tumour suppressive, CAV1 inhibits the MEK-ERK signalling55, 
and suppressive role of CAV1 may be observed in pancreatic and ovarian tumours, where CAV1 maintains E-cadherin 
expression stabilizing cell junctions30,56. This kind of cell-specific context-dependency is also reflected in the present 
study, where we show that CAV1 expression has strong inverse correlation with E-cadherin in KRT5-negative tumour 
cells, but weak positive correlation in KRT5-positive prostatic glands, which are mostly benign (see Figure 2).
In this study, we also investigated the upstream regulators of CAV1 in prostate cell lines by RNAi and sin-
gle cell quantitative imaging and found that beta1 integrins positively regulate CAV1 expression. The presence of 
beta1-interacting alpha-integrins (ITGA2, ITGA5, ITGA6), multiple integrin–actin linker proteins (e.g. PXN, ACTN1, 
PARVA, FLNA/C, PALLD), as well as signalling adaptors for integrins (e.g. ILK, PLAUR, CD44) as hits in the siRNA 
screen, further validate beta1 integrin regulation of CAV1 expression. We also show significant co-expression of CAV1 
and beta1 integrin proteins in prostate cell lines and translate this finding also to patient tissue samples using both con-
ventional IHC and multiplexed immunostainings with digital image analysis. CAV1 over-expression has been earlier 
associated with higher Gleason grade and progression of PCa32–34. We, however, could not show any association of 
CAV1 overexpression with either Gleason grade or pathological tumour stage. The reasons for this inconsistency could 
be due to a different antibody used. We used in this study a monoclonal antibody from BD (6100407; clone 2297), when 
Yang et al.33 and Karam et al.32 performed IHC with a rabbit polyclonal antibody from Santa-Cruz (antibody IDs not 
stated), and Moon et al.34 with a rabbit polyclonal antibody from BD (610059).
Do our in vitro observations translate to in vivo biology? PC3 and DU145 cell lines are derived from distant 
metastases, whereas PNT2 is an SV40-immortalized “normal” prostate cell line57–59. These cell lines do express 
CAV1, but for example exhibit poor expression levels of the androgen receptor – often reported as key for the pri-
mary PCa and metastatic progression60. Also, the fact that PNT2 cells exhibit low invasiveness61 suggests that CAV1 
is necessary but not sufficient per se to drive invasion. However, our results demonstrate that CAV1 upstream reg-
ulation is shared by these cell lines and that signalling programmes downstream of TGFβ are specifically impacted 
by CAV1 downregulation across the models. As the analysis of patient material shows a very strong association of 
high CAV1 expression with EMT hallmarks (i.e. downregulation of E-cadherin) as well as with the expression of 
beta1-integrins, we conclude that our in vitro models reflect the human in vivo biology for this part.
Overall, our results warrant for further parallel assessment of the expression of CAV1 and different integrins 
as well as the related genes identified in this work, to study whether a positive association could reflect clinical 
outcomes, and whether these signatures could be diagnostic/prognostic in PCa. Finally, our findings suggest that 
therapeutic inhibition of CAV1, TGFβ signalling, or its upstream regulatory network, could be beneficial for PCa 
patients with CAV1 over-expression.
Methods
Patient samples and conventional IHC. Ethical approval for the use of clinical data and samples 
was obtained from the Institutional Ethics Committee of Hospital District of Helsinki and Uusimaa (D:no 
446/13/03/02/2009), and by the Finnish agency for Health and Welfare (D:no THL490.5.05.00/2016) according to 
the national legislation. The use of the archived tissue blocks was approved by the National Supervisory Authority for 
Gleason score n (%) ITGB1 negative ITGB1 weak ITGB1 moderate ITGB1 strong χ2(p-value)
≤6 83 (25) 22 46 11 4
0.331
7 198 (58) 54 114 23 7
8≤ 57 (17) 25 25 5 2
Total1 338 (100) 101 185 39 13
Pathological stage n (%)
0.698
≤pT2 184 (59) 55 101 19 8
pT3≤ 128 (61) 35 71 18 4
Total2 312 (100) 91 172 37 12
Table 3. ITGB1 expression association with pathological variables in TMA_1. 1Patients who received neo-
adjuvant therapy or were missing Gleason score were removed from the analysis. 2Patients who received neo-
adjuvant therapy or were missing stage information were removed from the analysis.
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Welfare and Health (VALVIRA, D:no 4076/32/300/02), giving us a permission to apply old diagnostic leftover sam-
ples in research in an unlinked fashion with no patient identifiers preserved. Given the time frame from diagnostic 
sample processing to application in research, patient consent for the use of such samples is not possible nor needed 
due to the VALVIRA permission. The experiments conformed to the principles set out in the WMA Declaration of 
Helsinki and the Department of Health and Human Services Belmont Report. All FFPE samples were obtained from 
the Department of Pathology at the Helsinki University Hospital (HUH). Formalin fixation and paraffin embedding 
were performed in the central laboratory of HUH according to standard procedures. The samples were anonymous 
and all unique identifiers, including photos, were removed from the published images and figure legends.
Study population, conventional chromogenic immunohistochemistry methods, and tissue microarray con-
struction were previously published in detail49. The TMA_1 consisted of 435 patients (Table 1) with two 1 mm 
cores from the primary Gleason grade area (index lesion) and one from the secondary Gleason grade area. One 
core of each patient contained an adjacent benign area. The PCa TMA_2 consisted of 70 PCa patients with one 
1 mm core from the cancer area and another one from the adjacent benign area.
MicroArray datasets. Description of microarray datasets. The microarray data used in this study was acquired 
from three publicly available data repositories. We used each dataset at different stages of the study as described below:
 1. GeneSapiens database36 was used for the analysis of mesenchymal and epithelial expression clusters. The 
microarray data in Genesapiens database was processed as described in the original article36. We selected 
35 epithelial cell lines and 4 mesenchymal cell lines based on prior biological knowledge about these cell 
lines.
 2. GSK300 microarray dataset was used for the analysis of CAV1 correlating genes. The original raw data 
was generated under GlaxoSmithKline Cancer cell line Genomic profiling project. This raw data was 
downloaded from Cancer Biomedical Informatics Grid (caBig) portal and all samples were profiled using 
Affymetrix Human Genome U133 Plus 2.0 Array Platform. The raw CEL files data was normalized using 
the Aroma Affymetrix (Version 1.3.0) R package62 (http://www.aroma-project.org) based on custom CDF 
files (version 16) found at http://brainarray.mbni.med.umich.edu.
 3. Connectivity map (cmap) microarray dataset generated by Broad Institute (http://www.broadinstitute.
org/cmap/) shows the transcriptional responses of genes upon drug treatment. We did not use the already 
processed data in cmap database because the rank-based procedure described in the original Connectivity 
Map paper shows systematic amplification of measurements for low expressed genes. Even small differenc-
es in low intensities, which contain mostly noise, are ranked, and this has a significant impact on the iden-
tification of differentially expressed genes. Hence, we downloaded the raw data files in original CEL-format 
and re-processed them using Aroma Affymetrix R package as described above62. We used expression 
profiles from the most abundant microarray platform (HT-HG-U133A) in this dataset.
Microarray data analysis. Datasets 2 and 3 described above were RMA-normalized before computing dif-
ferential expression using the aroma.affymetrix62. The intensity values from the probesets mapping to a single 
gene were combined to get a single intensity value per gene using Tukey biweight. The already normalized data 
from Genesapiens database were further processed using canonical correspondence analysis (cca) by performing 
multi-dimension reduction using ANOVA-PCA approach. Differentially expressed genes between the mesenchy-
mal and epithelial group of cell lines were determined using the limma R/Bioconductor package. For the cmap 
dataset, we used the default Benjamini-Hochberg multiple testing correction method to filter out differentially 
expressed genes between un-treated and treated cell line data based on a q-value threshold (q < 0.05). We sorted 
the resulting data by the logarithmic fold change value (logFC) and took only genes with an absolute logFC > 1.5.
Antibodies in IHC. CAV1 BD6100407 (clone 2297) (1/1000 for IHC, 1/300 fluorescence). ITGB1 (EP1041Y; 
Ab52971; 1/500 IHC, 1/100 fluorescence). E-cadherin from CST (24E10, 1/300 fluorescence). The integrin anti-
bodies ITGA2 (Novus, NBP1-96715, 1/200) and ITGA6 (Novus, NBP1-85747, 1/200). The Pan-CK antibody 
(C-11, Abcam, ab7753, 1 to 1500) and the KRT5 antibody (Abcam, ab52635, 1 to 2000).
Antibodies in Western blotting. Antibodies against Cav1 (D46G3; 1/2000), E-cadherin (24E10; 1/2000), 
Slug (C19G7; 1/1000), pSmad3 (S423/425, 9520; 1/250), and CDK6 (3136; 1/500) were from CST. Pai-1(sc-5297; 
1/500), Smad2/3, (sc-8332; 1/500), p21 (sc-397; 1/500), and ITGB4 (sc-9090, 1/500) were from Santa-Cruz. 
Beta-tubulin (ab6046; 1/10 000), ITGB1 (EP1041Y; 1/5000), and PSF (ab38148; 1/1000) were from Abcam. Actin 
was from Sigma-Aldrich (A1978; 1/10 000), GAPDH from Millipore (MAB374; 1/3000), and DSP from Bethyl 
(A303-355A; 1/1000).
Multiplexed IHC. After heat-induced epitope retrieval (HIER) (see details from ref.35), slides were incu-
bated with primary antibody followed by washing and HRP-conjugated anti-mouse or anti-rabbit secondary 
antibodies (Immunologic, Netherlands). The HRP reaction was linked to Tyramide signal amplification (TSA) 
using tyramide-alexa-488 according to the manufacturer’s protocol (Life Technologies, TSA™ Reagent, Alexa 
Fluor® 488 Tyramide, T20948). Then, slides were heated as in HIER and incubated with two other primary anti-
bodies. Visualization for other than TSA-linked detection was based on AlexaFluor-conjugated anti-mouse and 
anti-rabbit antibodies (AlexaFluor-555, AlexaFluor-647, 1 to 500, Life Technologies) and Hoechst 33342 (1 µg/
ml) for nuclear signal. Slides were mounted using ProLong Gold antifade reagent (In vitrogen).
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Tissue analysis. For the conventional IHC, the visual inspection of CAV1 and ITGB1 expression (scale 
0–3) in TMA_1 was performed blinded to clinicopathological parameters by T.P. and S.B. Inconsistencies were 
agreed together with a certified pathologist specialized in urological cancers (T.M.) to reach consensus. CAV1 and 
ITGB1 expression scores in multiple cancer cores were averaged and categorized for the final score of a patient. 
Only patients with two or more cancer cores were included in the final analysis (n = 435). Due to detachment of 
benign cores or false representation (stroma only or cancer present), the final patient number for benign samples 
was n = 401. Only patients who had prostatectomy as the primary treatment and known Gleason score or patho-
logical tumour stage (pT) status, were included in the final analysis.
For fluorescent detection and quantification of CAV1 and E-cadherin, a MatLab-based image analytical algo-
rithm was developed. For each patient, 3–4 representative image regions positive for pan-cytokeratin (panCK) were 
selected for quantification, and benign and cancer epithelial areas were detected based on KRT5 expression, which 
is usually lost in prostate adenocarcinoma. For final results, both CAV1 and E-cadherin channel intensities were 
measured as the average protein expression intensity α (α = (total channel intensity)/ (total area)). For CAV1 and 
integrin co-expression analysis in FFPE sections, ImageJ was applied as following: TMA spots were manually seg-
mented from the background. The epithelium was segmented using panCK positivity and threshold was set using 
visual assessment. The stroma was defined as the inversion of the epithelial segmentation mask. Object areas were 
computed by default ImageJ watershed algorithm and particle analysis. Mean and median intensities were calculated 
within each object area, and for final results, areas larger than 100 pixels were included as true objects.
RNAi. The cell lines, PNT2, Du145, and PC-3 from ATCC, were maintained in RPMI 1640 (Gibco, 11875-
085) supplemented with 10% FBS (Gibco). siRNA-mediated cell silencing was done using Lipofectamine 
2000 or RNAiMAX reagents (Life Technologies) using 1 to 1000 of the transfection reagent and 10 nM 
siRNA (final conc.). siRNAs were ON-TARGETplus siRNAs from Dharmacon. siRNAs used for experiments 
other than RNAi screen were the following: siCAV1:GAGCUUCCUGAUUGAGAUUdTdT; siCAV1_2: 
AAGAGCTTCCTGATTGAGATT; siCTRL: ON-TARGETplus Non-targeting siRNA #1 and #2; siITGB1: 
J-004506-05, J-004506-06, J-004506-07, J-004506-08; ITGA2: J-004566-06, J-004566-08; siITGA5: J-008003-
08; siITGA6: J-007214-06; siKIND-2: J-012753-05; siFOSL1: J-004341-06, J-004341-07, J-004341-08), where 
the code is the dublex catalog number for Dharmacon siRNAs. Alternatively, CAV1 was silenced using a 
lentiviral system (L-shCAV1), where target sequence corresponded to human CAV1 nucleotides 254–277 
(‘5-GACGTGGTCAAGATTGACTTT-3’). This sequence was cloned into pLVX-shRNA2, which contains a 
ZsGreen1 reporter (Clontech, Mountain View, CA). The use of this construct has been well-documented63,64. 
Lentiviral infection was performed as in63. The siRNA sequences used in the siRNA screen can be found in the 
Supplementary Table S8. The RNAi screen methodology was done as described in65.
3D invasion assays. The 3D invasion assays were done as described earlier63,66 with minor modifications. 
Briefly, 7000 cells were applied onto Ibidi (Angiogenesis) chambers, and after 3 h attachment, either Matrigel (50%) 
or Collagen type I (1.5 mg/ml, BD) was applied (25 µl) on top of the cells for 3 h, after which 25 µl of medium was 
added on top with daily addition of serum or TGFβ to create gradient. After incubation for 3 days (p21 determi-
nation) or 4 days (invasion assay), cells were either lysed for Western blotting or fixed for immunocytochemistry 
or IF. For lysis, collagen and Matrigel were first solubilized using 0.01 M HCL or cold PBS + 0.02 M EDTA, respec-
tively, and cells were collected and lysed with Laemmli buffer. For IF, cells were fixed with 4% paraformaldehyde 
PBS (PFAH-PBS), permeabilised with Triton-X100 (0.3%) and stained using Hoechst 33342 and Phalloidin-647 
(InVitrogen). Imaging was done using SP5 Leica confocal microscope with 20x objective by imaging the centre area 
of each well. Images were analysed using ImageJ. Invasiveness was quantified as the area invaded. Total number of 
cells at the end point was quantified by counting the nuclei in all of the acquired planes using 3D cell count plugin 
(ImageJ). For IHC, cells were fixed with 8% PFAH-PBS for 20 min, fixative inactivated with TRIS-EDTA (50 mM, 
2 mM), and gel pieces collected for paraffin processing using Shandon Cytoblocks (Thermo Scientific, 7401150).
MicroArray for CAV1 vs. Control silenced cells. To study the differential expression of genes in 
PC-3 cells silenced with shCAV1 or shCTRL, the following was done. RNA was purified from cells with stable 
knock-down of CAV1 (L-shCAV1) or from control cells (L-shCTRL) (3 days adherent cultures with passage 
4 after transfection, 80% confluent when collecting, the experiment was done in three replicates). One-Color 
Microarray-Based Gene Expression Analysis Protocol (Agilent Technologies, Palo Alto, CA, USA) was used to 
amplify and label RNA. Briefly, 1000 ng of total RNA from different samples were reverse transcribed using T7 
promoter primer and the Moloney murine leukemia virus (MMLV) reverse transcriptase (RT). cDNA was then 
converted to anti-sense RNA (aRNA) by using T7 RNA polymerase that amplifies target material and incor-
porates cyanine 3 (Cy3)-labeled CTP simultaneously. Samples were hybridized to a Whole Human Genome 
Microarray 4 × 44 K (G4112F, Agilent Technologies). 1.65 micrograms of Cy3-labeled aRNA was hybridized for 
17 hours at 65 °C in Agilent hybridization oven (G2545A, Agilent Technologies) set to 10 rpm in a final concen-
tration of 1 × GEx Hybridization Buffer HI-RPM (Agilent Technologies). Arrays were washed and dried out 
using a centrifuge according to manufacturer’s instructions (One-Color Microarray-Based Gene Expression 
Analysis, Agilent Technologies). Arrays were scanned at 5 mm resolution on an Agilent DNA Microarray Scanner 
(G2565BA, Agilent Technologies) using the default settings for 4 × 44 k format one-color arrays. Images provided 
by the scanner were analysed using Feature Extraction software v10.1.1.1 (Agilent Technologies).
For data analysis, raw signals were thresholded to 1 and quantiles normalization67 was performed using the 
software GeneSpring. Data were considered in the log2 scale. Default flags were considered as absent, except 
saturated points that were flagged as marginal. From the initial 41081 probes present in the Agilent 4 × 44 K chip, 
23702 remained after applying three types of filter:
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 1. By expression
Retain those genes where at least 100 percent of samples in any 1 out of 4 conditions have values within the 
accepted intensity range ([20,100] percentiles): 33064 probes remain.
 2. By flags
Retain those genes where at least 100 percent of samples in any 1 out of 4 conditions have reliable values 
(Present and Marginal Flags). 30838 probes remain.
 3. By error
Retain only those genes that change across the experiment, i.e. with coefficient of variation (CV) > 1% across 
all samples. 23702 probes remain.
Quantitative reverse transcriptase PCR. Total RNA was extracted using the RNeasy plus mini kit 
(Qiagen 74134) and the cDNA was obtained from 1 ug of total RNA by using an Omniscript RT kit (Qiagen 
205111). Quantitative PCR was carried out in a 7900 HT Fast Real-time PCR System (Applied Biosytems) using 
a power SYBR Green PCR master mix (Applied biosytems 4367659) and the following specific primer sets with 
FOR and REV primers, respectively: 5′-atccacagctgtcatagtc-3′ and 5′-cacttggcccatgaaaag-3′ for SERPINE1; 
5′-cagtgattatttccccgtatc-3′ and 5′-ccccaaagatgaggagtatc-3′ for SNAI2 (SLUG); 5′-gagagagaggaaggagattc-3′ 
and 5′-gagtttctccctgaaatgtg-3′ for EDN1; 5′-aggcacagatgttaaagatg-3′ and 5′-ccgagatattatttctgcatgg-3′ for 
ADARB1; 5′-aactaacttctcccccatac-3′ and 5′-cttaaaaggctctgccttag-3′ for OAS2; 5′-ttgtatactaccatagtgagcc-3′ and 
5′-tttggagaaaacagaacacc-3 for AGR2; 5- gacaagaagtactaccccag-3 and 5-gagatcaagggaatgttcaag for BST2. For nor-
malization of the signals, ACTIN 5′-caccttccagcagatgtcga-3′ and 5′-agcatttgcggtggatgg-3′, as well as GAPDH 
5′-atcaccatcttccaggagcg-3′ and 5′-cctgcaaatgagccccag-3′ were used. The PCR program applied 40x cycles of 
95°10 min/95°15 s, 60°1 min/95°15 s, 60°15 s, and 95. Biogazelle qbaseplus program was used to analyze and nor-
malize the data.
Statistics. The normality of data was tested using Shapiro-Wilk test. For normally distributed data, Student´s 
t-test (two-sided) was employed to compare mean expression between groups. For non-normally distributed 
data, Welch’s one-way ANOVA was employed to compare mean expression between groups. We used Pearson 
Chi-square to test significance of cross-tabulations for nominal and categorical data. Spearman rho was used for 
correlation analysis between categorical variables. For microarray gene expression analysis extracted from data-
bases, we performed correlation analysis of CAV1 across the whole transcriptome of genes using the Pearson cor-
relation method across over 300 cell line samples in the GSK300 dataset. We selected the top 500 genes having a 
correlation score (r > 0.3) for gene set enrichment analysis in the David gene ontology analysis portal. The limma 
package from Bioconductor was used for cDNA microarray statistics68. Limma calculates moderated t-statistics, 
adding to the error term some information on the variance of all genes, solving the typical microarray prob-
lem of small sample size. For tissue image analysis and for RNAi cell screen image analysis standard two-sided 
(two-tailed) Student’s t test was used. P-values <0.05 were considered statistically significant.
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